New pill shows promise for rare blood cancer in Late-Stage trial

NCT ID NCT03703375

Completed Disease control Sponsor: Celgene Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 study tested an oral drug called azacitidine (CC-486) against standard treatments in 93 adults with a rare T-cell lymphoma that had relapsed or stopped responding. The main goal was to see if the drug could delay cancer progression or death. Participants were randomly assigned to receive either the study drug or a treatment chosen by their doctor.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

angioimmunoblastic T-cell lymphoma lymphoma Nodal T-follicular helper cell lymphoma, follicular type T-cell non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LYMPHOMA, T-CELL

Contacts and locations

Locations

Local Institution - 40122

Isehara City, Kanagawa, 259-1193, Japan
Local Institution - 40222

Koto-ku, Tokyo, 1358550, Japan
Local Institution - 40722

Chuo-ku, Tokyo, 104-0045, Japan
Local Institution - 40922

Fukuoka, 812-8582, Japan
Local Institution - 41222

Sendai, 980-8574, Japan
Local Institution - 41322

Tsukuba, 305-8576, Japan
Local Institution - 41422

Hidaka, Saitama-Pref, 350-1298, Japan
Local Institution - 41522

Kashiwa, 277-8577, Japan
Local Institution - 41622

Nagoya, 460-0001, Japan
Local Institution - 41722

Sayama, Osaka, 5898511, Japan
Local Institution - 41822

Sapporo, Hokkaido, 0608648, Japan
Local Institution - 41922

Okayama, Okayama-ken, 700-8558, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.